Abstract
Glioblastoma is the most frequent and aggressive primary brain tumor in adults. Recently, a growing number of studies have shown that denaturation profile of plasma samples obtained by differential scanning calorimetry (DSC) can represent a signature of a disease. In this study, we analyzed for the first time the DSC denaturation profiles of the plasma from patients with recurrent glioblastoma (n=17). Comparison to the one of healthy individuals (n=10) and to already described profiles in others cancer showed clear differences suggesting that this DSC profile may constitute a signature of glioblastoma. Parameters extracted from these profiles were used for cluster analysis which revealed the existence of glioblastoma profile subgroups which correlated with prognostic factors. Moreover, we showed that the presence of circulating bevacizumab and carmustine did not alter this calorimetric signature of the disease, indicating that an evolution of the profile could be followed without being masked by ongoing systemic treatment. Thus, our results constitute a very promising proof of principle that a specific calorimetric profile could be detected in the plasma of glioblastoma patients. Moreover, we believe that our findings point to a potential easy-to-use non-invasive monitoring tool for glioblastoma patients.
Highlights
Glioblastoma (GB) is the most frequent and aggressive primary brain tumor in adults
Patient cohort was composed of 17 GB patients with a median age of 62.5 years and a median Karnofsky Performance Status (KPS) of 70 at relapse
Plasma samples from 10 healthy individuals and 17 GB patients were analyzed by differential scanning calorimetry (DSC) to obtain denaturation profiles
Summary
Glioblastoma (GB) is the most frequent and aggressive primary brain tumor in adults It is characterized by cellular atypia, severe necrosis, and high rate of angiogenesis [1]. Few treatment options are available and remain associated with heterogeneous response rates [3] In this indication, the use of bevacizumab is associated with favorable response rate and improved progressionfree survival [4, 5]. The use of bevacizumab is associated with favorable response rate and improved progressionfree survival [4, 5] In this context of limited systemic therapies, accurate and timely detection of the disease recurrence is crucial in order to optimize the therapeutic options and to improve the patient management. The identification of a new easy-to-use method to monitor glioblastoma evolution is an urgent need in the neurooncology field
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
